Historique
Périodique
A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence
(Essai thérapeutique placebo contrôlé du celecoxib pour le traitement de la dépendance à la cocaïne)
Auteur(s) :
M. S. REID ;
B. ANGRIST ;
S. BAKER ;
WOO C. ;
M. SCHWARTZ ;
A. MONTGOMERY ;
M. D. MAJEWSKA ;
J. ROBINSON ;
J. ROTROSEN
Article en page(s) :
32-42
Sous-type de document :
N° spécial de revue / Special issue of a journal
Refs biblio. :
37
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Thésaurus mots-clés
COCAINE
;
DEPENDANCE
;
PHARMACOTHERAPIE
;
MEDICAMENTS
;
ESSAI THERAPEUTIQUE
;
PLACEBO
Note générale :
Addiction, 2005, 100, (Suppl. 1 Clinical Rapid Efficacy Screening Trials (CREST)), 32-42
Note de contenu :
graph. ; tabl.
Résumé :
ENGLISH :
Aims : To conduct a medication screening trial study on the efficacy of celecoxib versus placebo for the treatment of cocaine dependence. Design : A modified blinded, parallel group study in an outpatient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting : The study was performed at the New York Medications Development Research Unit (MDRU). Participants : All participants met Diagnostic and Statistical Manual version IV (DSM-IV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Twenty-three participants were enrolled in the treatment phase of the study. Intervention : After a 2-week screening period, subjects were assigned randomly to receive either celebrex (200 mg/day) or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements : Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs and extrapyramidal side-effects tests. Results : Study retention was similar across both treatment groups and safety measures indicated that celecoxib was moderately tolerated. Cocaine use, as measured by self-report and urine BE levels at end of treatment, indicated weaker improvement in the celecoxib group. Reductions in the intensity of cocaine craving were also weaker in the celecoxib group. Cocaine abstinence rates, global impression scores and all other related psychometric measures did not differ significantly between treatment groups. Conclusion : This study does not support the effectiveness of celecoxib for the treatment of cocaine dependence. (Review' s abstract)
ENGLISH :
Aims : To conduct a medication screening trial study on the efficacy of celecoxib versus placebo for the treatment of cocaine dependence. Design : A modified blinded, parallel group study in an outpatient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting : The study was performed at the New York Medications Development Research Unit (MDRU). Participants : All participants met Diagnostic and Statistical Manual version IV (DSM-IV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Twenty-three participants were enrolled in the treatment phase of the study. Intervention : After a 2-week screening period, subjects were assigned randomly to receive either celebrex (200 mg/day) or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements : Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs and extrapyramidal side-effects tests. Results : Study retention was similar across both treatment groups and safety measures indicated that celecoxib was moderately tolerated. Cocaine use, as measured by self-report and urine BE levels at end of treatment, indicated weaker improvement in the celecoxib group. Reductions in the intensity of cocaine craving were also weaker in the celecoxib group. Cocaine abstinence rates, global impression scores and all other related psychometric measures did not differ significantly between treatment groups. Conclusion : This study does not support the effectiveness of celecoxib for the treatment of cocaine dependence. (Review' s abstract)
Affiliation :
Department of Psychiatry New York University School of Medicine VA NYHHS 116 A, 423 E. 23rd Street New York NY 10010 ; malcolm.reid@med.va.gov
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |